SELLAS's Peptide Vaccine Galinpepimut-S Cut the Risk of Death 41% in Phase 3 REGAL Trial in Acute Myeloid Leukemia
In 126 people with acute myeloid leukemia in second or later remission, or in remission but unable to have a stem cell transplant, the off-the-shelf vaccine made of four WT1-derived peptides was linked to median overall survival of 24 months, versus 14.7 months on investigators' choice of best available treatment, BioSpace reported. The open-label trial met its primary endpoint, and SELLAS said it will discuss a possible accelerated path to approval with the FDA. The vaccine was invented at Memorial Sloan Kettering, which has a financial interest in SELLAS.